the Safety and Efficacy of Targeted BCMA In Vivo LV Injection for Recurrent or Refractory Autoimmune Diseases

NCT07339540 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Recurrent or Refractory Systemic Lupus Erythematosus
Recurrent or Refractory IgG4 Related Diseases
Recurrent or Refractory Systemic Sclerosis
Recurrent or Refractory Idiopathic Inflammatory Myopathy
Recurrent or Refractory ANCA Associated Vasculitis

Interventions

DRUG: V001-BCMA

Sponsor

Tongji Hospital